{"schema_version":"secwatch.filing_event.v1","accession":"0001731122-23-001841","form_type":"8-K","ticker":"LNAI","cik":"0001527728","company_name":"Lunai Bioworks Inc.","filed_at":"2023-10-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.376553+00:00","generated_at":"2026-06-10T02:17:46.839838+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Renovaro raises $2M via 5% OID convertible notes at 12% interest, due Sept 2024","bullets":["Aggregate principal $2,105,264; gross proceeds $2,000,000 after 5% original issue discount.","Notes bear 12% annual interest and mature September 5, 2024; convertible only upon Qualified Offering (≥$10M) or at maturity.","Conversion price at 95% of Qualified Offering price or closing price at maturity, subject to floor of $4.50 per share.","One note issued Sept 5, 2023 for $526,316 has a floor at 105% of Nasdaq closing price preceding issuance.","Notes sold to five non-U.S. persons under Regulation S; proceeds for therapy development and working capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-23-001841","json":"https://secwatch.observer/filing/0001731122-23-001841.json","markdown":"https://secwatch.observer/filing/0001731122-23-001841.md","text":"https://secwatch.observer/filing/0001731122-23-001841.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527728/000173112223001841/0001731122-23-001841-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527728/000173112223001841/e5116_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T02:17:46.839838+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1650d73e82ee7bfbc633903617fb2bfadee51907","claim":"Lunai Bioworks Inc. incurred convertible notes of $2,105,264 with five investors at 12% per annum maturing September 5, 2024.","evidence_excerpt":"Agreements with five investors (the “Investors”) to purchase 5% Original Issue Discount Convertible Promissory Notes (the “Notes”) for an aggregate principal amount of $2,105,264. The Company received a total of $2,000,000 in gross proceeds from the offering, taking into account the 5% original issue discount. The Notes bear an interest rate of 12%","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112223001841/0001731122-23-001841-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$2,105,264"},{"label":"Counterparty","value":"five investors"},{"label":"Rate","value":"12% per annum"},{"label":"Maturity","value":"September 5, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"d064e30f3e3794ab25115b204006d104cdad5bac","claim":"Lunai Bioworks Inc. entered into Subscription Agreements with five investors valued at aggregate principal amount of $2,105,264 (effective 2023-09-05).","evidence_excerpt":"Between September 5, 2023 and October 5, 2023, Renovaro Biosciences Inc. (the “Company”) entered into Subscription Agreements with five investors (the “Investors”) to purchase 5% Original Issue Discount Convertible Promissory Notes (the “Notes”) for an aggregate principal amount of $2,105,264.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112223001841/0001731122-23-001841-index.htm","confidence":1.0,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"five investors"},{"label":"Value","value":"aggregate principal amount of $2,105,264"},{"label":"Effective","value":"2023-09-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}